Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene Corporation완전한
-
Celgene Corporation완전한
-
Celgene Corporation완전한
-
Celgene Corporation종료됨
-
Celgene Corporation완전한골수이형성 증후군미국, 덴마크, 호주, 벨기에, 체코 공화국, 프랑스, 독일, 그리스, 이탈리아, 네덜란드, 러시아 연방, 스페인, 스웨덴, 스위스, 영국
-
Celgene Corporation완전한다발성 골수종아일랜드, 스페인, 호주, 오스트리아, 영국